Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/2/2025

Osteoporosis Treatment Guidelines

Non-Pharmacological Interventions

  • The American College of Rheumatology recommends ensuring adequate calcium intake of 1,000-1,200 mg/day through diet and supplementation if necessary 1, 2
  • Vitamin D supplementation of 800 IU/day is recommended to maintain serum levels ≥20 ng/ml 1, 2, 3
  • A balanced diet, smoking cessation, limitation of alcohol intake to 1-2 beverages/day, and regular weight-bearing and resistance training exercise are recommended lifestyle modifications 1, 2, 4

Pharmacological Interventions

  • The American College of Rheumatology recommends oral bisphosphonates (alendronate or risedronate) as first-line therapy for osteoporosis treatment 1, 2
  • Zoledronic acid (intravenous bisphosphonate) and denosumab (subcutaneous injection) are considered for patients with oral intolerance, difficulty with administration, or non-compliance 1, 2
  • Anabolic agents such as teriparatide are considered for very severe osteoporosis with recent fractures or very high fracture risk 1, 2, 5

Special Considerations

  • Orthogeriatric co-management is recommended for frail elderly patients with multiple comorbidities and polypharmacy 1, 6
  • Early rehabilitation is crucial to regain mobility and independence after a fracture 1, 6
  • Regular monitoring for medication tolerance and adherence is essential 1, 2

Monitoring and Follow-up

  • Clinical fracture risk reassessment should be performed every 12 months 4
  • Bone mineral density (BMD) testing should be considered every 1-3 years depending on risk factors 4, 7
  • Patient education about the disease burden, risk factors, and importance of treatment adherence is critical 1, 6

Important Caveats

  • Calcium supplementation alone has no demonstrated effect on fracture reduction and may be associated with gastrointestinal side effects 1, 2
  • There is uncertainty whether high calcium intake is associated with cardiovascular events 1, 2
  • Long-term adherence to drug treatment is often poor, necessitating systematic follow-up 1, 2
  • For patients with renal impairment, medication choice may need adjustment 5, 8
  • The benefits of fracture prevention must be weighed against potential medication side effects, particularly in very elderly patients 5